NASDAQ:TXMD - TherapeuticsMD Stock Price, Forecast & News

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

TherapeuticsMD Inc (NASDAQ:TXMD) released its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.19) by $0.06. The firm earned $8.21 million during the quarter, compared to analyst estimates of $8.05 million. TherapeuticsMD had a negative net margin of 427.70% and a negative return on equity of 430.28%. The business's revenue for the quarter was up 136.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.16) EPS. View TherapeuticsMD's Earnings History.

TherapeuticsMD is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for TherapeuticsMD.

9 brokers have issued 12-month target prices for TherapeuticsMD's stock. Their forecasts range from $3.00 to $17.00. On average, they expect TherapeuticsMD's stock price to reach $9.11 in the next year. This suggests a possible upside of 270.4% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.

News articles about TXMD stock have been trending somewhat negative on Friday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. TherapeuticsMD earned a news impact score of -1.9 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for TherapeuticsMD.

TherapeuticsMD saw a increase in short interest in December. As of December 31st, there was short interest totalling 86,820,000 shares, an increase of 9.4% from the December 15th total of 79,360,000 shares. Based on an average daily volume of 3,650,000 shares, the days-to-cover ratio is currently 23.8 days. Approximately 36.6% of the company's shares are short sold. View TherapeuticsMD's Current Options Chain.

Some companies that are related to TherapeuticsMD include Uniqure (QURE), ChemoCentryx (CCXI), ArQule (ARQL), Zogenix (ZGNX), Amicus Therapeutics (FOLD), Karuna Therapeutics (KRTX), Epizyme (EPZM), Arena Pharmaceuticals (ARNA), Ra Pharmaceuticals (RARX), Heron Therapeutics (HRTX), Synthorx (THOR), Aurinia Pharmaceuticals (AUPH), Turning Point Therapeutics (TPTX), Eidos Therapeutics (EIDX) and Aimmune Therapeutics (AIMT).

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Cleveland-Cliffs (CLF), CannTrust (CNTTF), NVIDIA (NVDA), Horizon Therapeutics (HZNP), bluebird bio (BLUE), Global Blood Therapeutics (GBT) and Novavax (NVAX).

TherapeuticsMD's stock is owned by many different of institutional and retail investors. Top institutional investors include Sanders Morris Harris LLC (0.14%) and Janney Montgomery Scott LLC (0.05%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Group L P Column, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.

TXMD stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC. View Insider Buying and Selling for TherapeuticsMD.

TXMD stock was acquired by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Group L P Column, Jane F Barlow, John CK Iv Milligan, Robert G Finizio and Tommy G Thompson. View Insider Buying and Selling for TherapeuticsMD.

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TXMD stock can currently be purchased for approximately $2.46.

TherapeuticsMD has a market capitalization of $667.10 million and generates $16.10 million in revenue each year. The company earns $-132,620,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. TherapeuticsMD employs 241 workers across the globe.View Additional Information About TherapeuticsMD.

The official website for TherapeuticsMD is http://www.therapeuticsmd.com/.

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected]